139306-10-8
139306-10-8
Chemical Structure
Rivastigmine metabolite
Synonym(s): NAP 226-90
- CAS No.: 139306-10-8
- Formula:C10H15NO
- Molecular Weight:165.23
IUPAC Name: (S)-3-(1-(dimethylamino)ethyl)phenol
InChIKey: GQZXRLWUYONVCP-QMMMGPOBSA-N
SMILES: OC1=CC=CC([C@@H](N(C)C)C)=C1
Biological Activity: Rivastigmine metabolite (NAP 226-90) is a metabolite produced by the hydrolysis of Rivastigmine (HY-17368). Rivastigmine metabolite serves as a surrogate marker to track the bioavailability, metabolic extent, and transdermal patch delivery rate of Rivastigmine[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Rivastigmine metabolite | 99.01% | Rivastigmine metabolite (NAP 226-90) is a metabolite produced by the hydrolysis of Rivastigmine (HY-17368). Rivastigmine metabolite serves as a surrogate marker to track the bioavailability, metabolic extent, and transdermal patch delivery rate of Rivastigmine. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rivastigmine metabolite (Standard) | ≥98% | Rivastigmine metabolite (Standard) is the analytical standard of Rivastigmine metabolite. This product is intended for research and analytical applications. Rivastigmine metabolite (NAP 226-90) is a metabolite produced by the hydrolysis of Rivastigmine (HY-17368). Rivastigmine metabolite serves as a surrogate marker to track the bioavailability, metabolic extent, and transdermal patch delivery rate of Rivastigmine. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rivastigmine metabolite-d6 | Rivastigmine metabolite-d6 (NAP 226-90-d6) is a deuterated form of Rivastigmine metabolite. Rivastigmine metabolite (NAP 226-90) is a metabolite produced by the hydrolysis of Rivastigmine (HY-17368). Rivastigmine metabolite serves as a surrogate marker to track the bioavailability, metabolic extent, and transdermal patch delivery rate of Rivastigmine. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Polinsky RJ, et al. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998;20(4):634-647. [Content Brief]
- [2]. Srinivas NR, et al. Transdermal Rivastigmine Delivery for Alzheimer Disease: Amenability of Exposure Predictions of Rivastigmine and Metabolite, NAP226-90, by Linear Regression Model Using Limited Samples. Clin Neuropharmacol. 2016;39(4):169-177. [Content Brief]
